These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.
What is GLP-3?
Key Research
Specifications
Property | Details |
---|---|
CAS Number | Not assigned for this research analog; see lot COA |
PubChem CID | Not assigned for this research analog; see lot COA |
Molecular Formula | Sequence- and salt-dependent (reported on COA) |
Molecular Weight | Sequence- and salt-dependent (reported on COA) |
Physical Appearance | White to off-white lyophilized powder |
Form | Synthetic peptide (triple agonist) |
Container | 3 mL glass vial (10 mg net content) |
Purity | ≥99% by HPLC; identity by MS (batch COA via on-vial QR) |
Solubility | Soluble in sterile water or neutral aqueous buffers; gentle inversion/brief sonication may aid dissolution. If required by your SOP, 0.22 µm filter after reconstitution. |
Intended Use | Laboratory research only (RUO). Not for human or animal use. |
FAQ
How much is in each vial?
Does it come with instructions?
What other supplies are needed?
How long does a vial last?
Is this the same as clinical retatrutide?
Can you share the exact sequence?
Which in-vitro assays is this commonly used in?
References
- Coskun, T., et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist, robustly reduces body weight via enhanced energy expenditure in preclinical models.” Cell Metabolism 34(10), 2022, 1486–1501.e7 [Link]
- Frias, J. P., et al. “LY3437943, a triple glucagon, GIP, and GLP-1 receptor agonist, in people with type 2 diabetes: a randomised, placebo-controlled, multiple ascending dose phase 1b trial.” The Lancet Diabetes & Endocrinology 10(12), 2022, 873–884. [Link]
- Jastreboff, A. M., et al. “Triple–Hormone–Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” New England Journal of Medicine 389(2), 2023, 132–144. [Link]
- Wu, X., et al. “Structural insights into the triple agonism at GLP-1R, GIPR and GCGR by the dual-incretin agonist LY3437943 (Retatrutide).” Nature Structural & Molecular Biology 31(8), 2024, 702–712 [Link]
- Neuser, D., et al. “Inotropic effects of the triple agonist retatrutide (LY3437943) in isolated human atrial preparations.” Frontiers in Pharmacology 16, 2024, Article 1403874. [Link]
Why Buy from USA Peptides Direct
- USA Made
- Same-Day Shipping (Mon–Fri, on in-stock items)
- GMP-Standard lyophilization, documented & traceable
- 24/7 Support
- Price Match Guarantee
- Batch Tracking with QR Code Verification
- 3rd-Party U.S. Lab Testing — purity, quantity, endotoxin
- Cold-Chain Shipping — Always (no paid upgrade)
- All Major Payments Accepted
- Text & Email Order Updates
- 2-Day FedEx/UPS Shipping Standard
- Cheapest Overnight Rates
- Large Variety of Peptides & Bioregulators
Quality, Storage & Handling
Each lot is confirmed by HPLC (purity) and MS (identity); QR on the vial links to the batch COA. Independent U.S. labs verify purity, quantity, and endotoxin.
- Storage (lyophilized): −20 °C long-term or 2–8 °C short-term; keep desiccated and protected from light.
- After reconstitution: Use neutral, oxygen-poor buffer when possible; aliquot and store at ≤−20 °C; avoid repeated freeze–thaw.
- Working solutions: Prepare fresh; minimize exposure to light/alkaline pH to reduce degradation.
Shipping
Ships in validated cold-chain packaging. In-stock orders placed before the daily cutoff dispatch the same day. 2-Day FedEx/UPS is standard, with overnight options available. Automated text/email updates included.
Compliance & Research Use Only Disclaimer
For laboratory research only. All articles are product information provided on this website are for informational and educational purposes only. Not a drug, cosmetic, food, or household chemical. Not for human or animal use, diagnostic, or therapeutic applications. Buyers warrant they are qualified to handle RUO materials under applicable laws and institutional guidelines. COAs available via QR or upon request.